Free Trial

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

BioMarin Pharmaceutical logo
$57.25 +0.08 (+0.14%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$57.24 -0.01 (-0.01%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

Key Stats

Today's Range
$57.03
$58.07
50-Day Range
$54.08
$63.69
52-Week Range
$52.93
$94.85
Volume
1.38 million shs
Average Volume
1.73 million shs
Market Capitalization
$10.98 billion
P/E Ratio
17.91
Dividend Yield
N/A
Price Target
$93.61
Consensus Rating
Moderate Buy

Company Overview

BioMarin Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

BMRN MarketRank™: 

BioMarin Pharmaceutical scored higher than 99% of companies evaluated by MarketBeat, and ranked 19th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 18 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioMarin Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

  • Read more about BioMarin Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioMarin Pharmaceutical is 21.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioMarin Pharmaceutical is 21.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

  • Price to Earnings Growth Ratio

    BioMarin Pharmaceutical has a PEG Ratio of 0.79. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    BioMarin Pharmaceutical has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioMarin Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    2.32% of the float of BioMarin Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioMarin Pharmaceutical has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioMarin Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    BioMarin Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.32% of the float of BioMarin Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioMarin Pharmaceutical has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioMarin Pharmaceutical has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for BioMarin Pharmaceutical this week, compared to 12 articles on an average week.
  • Search Interest

    16 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,651.00 in company stock.

  • Percentage Held by Insiders

    Only 0.85% of the stock of BioMarin Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioMarin Pharmaceutical's insider trading history.
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Morgan Stanley
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
BMRN BioMarin Pharmaceutical Inc. - Seeking Alpha
See More Headlines

BMRN Stock Analysis - Frequently Asked Questions

BioMarin Pharmaceutical's stock was trading at $65.73 at the beginning of 2025. Since then, BMRN stock has decreased by 12.9% and is now trading at $57.25.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The biotechnology company earned $747.31 million during the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 17.76% and a trailing twelve-month return on equity of 11.34%.
Read the conference call transcript
.

Top institutional investors of BioMarin Pharmaceutical include Central Pacific Bank Trust Division and Kera Capital Partners Inc.. Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, Cristin Hubbard, V Bryan Lawlis, Erin Burkhart and Mark J Alles.
View institutional ownership trends
.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO).

Company Calendar

Last Earnings
2/19/2025
Today
7/05/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BMRN
Employees
3,040
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$93.61
High Stock Price Target
$126.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+63.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
24 Analysts

Profitability

Trailing P/E Ratio
21.28
Forward P/E Ratio
18.17
P/E Growth
0.79
Net Income
$426.86 million
Pretax Margin
22.86%

Debt

Sales & Book Value

Annual Sales
$2.85 billion
Cash Flow
$3.23 per share
Price / Cash Flow
17.71
Book Value
$29.69 per share
Price / Book
1.93

Miscellaneous

Free Float
190,146,000
Market Cap
$10.98 billion
Optionable
Optionable
Beta
0.17

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BMRN) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners